Premium
Design, synthesis and iodination of an Arg‐Arg‐Leu peptide for potential use as an imaging agent for human prostate carcinoma
Author(s) -
Yu MingMing,
Wang RongFu,
Yan Ping,
Zhang ChunLi,
Liu Meng,
Cui YongGang
Publication year - 2008
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1542
Subject(s) - chemistry , peptide , biodistribution , sephadex , prostate cancer , prostate , arginine , amino acid , biochemistry , cancer , medicine , in vitro , enzyme
The aim of this work was to design and synthesize a radioiodinated peptide containing arginine–arginine–leucine (RRL) functionality as a potential imaging agent of tumor angiogenesis. The RRL peptide was synthesized using the Fmoc solid phase method and identified by MS analysis after purification by HPLC. The RRL peptide was labeled with 131 I by the Chloramine‐T method and purified through Sephadex G‐25 column. Furthermore, the 131 I labeled peptide was used to evaluate its biodistribution. SPECT imaging was carried out at 24 h after the 131 I labeled RRL peptide was injected into BALB/c nude mice bearing human prostate carcinoma. For the first time we have shown that a radiolabelled RRL peptide appears to be useful as a tumor angiogenic endothelium imaging agent for the diagnosis of the human prostate carcinoma. Copyright © 2008 John Wiley & Sons, Ltd.